The results will hopefully clarify the utility of blinatumomab in these patients, and also regarding the lineage switch with the outgrowth of myeloid leukemia that several groups have described for KMT2A-rearranged leukemias under the selective pressure of blinatumomab [36,42,45]. This evidence concerns the gene KMT2A and myeloid leukemia.